Omics sciences such as metabolomics, lipidomics, and proteomics play a key role in biomedical and health research, enabling a deeper understanding of the molecular mechanisms associated with human health and disease. These approaches help research teams explore biological pathways, characterize molecular phenotypes, and generate insights that advance knowledge across health-related research areas.
In biomedical and health research, omics technologies are widely applied in basic, translational, and population-based research settings, including studies involving experimental models and well-characterized research cohorts. By providing high-resolution molecular data, omics approaches support the identification of molecular signatures, the study of disease-associated mechanisms, and the discovery of research biomarkers.
At oloBion, we apply advanced multi-omics strategies to support research-focused projects in biomedical and health research. Our services are designed to generate robust analytical data that empower scientific teams to address complex biological questions, bridging fundamental research with translational applications in health-related research contexts.
Lipid biomarkers for disease-related research: Identification of lipid-based molecular signatures associated with metabolic, neurological, and cardiovascular research models to support the study of disease-related biological processes.
Inflammation and immune system research: Study of lipid mediators involved in inflammatory pathways and immune responses, supporting research in immunology and inflammation-related conditions.
Neurodegenerative disease research and brain health: Analysis of lipid alterations associated with neurodegenerative research contexts, including Alzheimer’s, Parkinson’s, and other neurological disease models.
Lipid metabolism and cardiometabolic research: Investigation of cholesterol, fatty acids, and phospholipids in cardiometabolic and metabolic syndrome research models to support the study of lipid-driven pathways associated with metabolic dysfunction and cardiovascular risk in research and translational settings.
Biomarker discovery in disease-related research: Identification of metabolic signatures associated with cancer, metabolic disorders, and neurodegenerative research contexts through advanced metabolomic profiling.
Translational and precision research: Investigation of inter-individual metabolic responses to compounds, diet, and experimental interventions in translational and population-based research settings.
Pharmacometabolomics and drug discovery research: Analysis of metabolic responses related to compound exposure and metabolism to support early-stage drug discovery and preclinical research programs.
Gut microbiome and metabolic health research: Investigation of microbially derived metabolites and their role in host metabolism, immunity, and metabolic research models.
Nutrition and cardiometabolic research: Assessment of metabolic pathways involved in obesity, diabetes, and cardiovascular disease research to support nutrition-focused research studies.
Protein biomarker discovery in disease-related research: Identification and characterization of proteins associated with cancer, infectious disease models, and genetic research contexts.
Protein-based drug discovery research: Support for early-stage drug discovery through the study of protein targets, signaling pathways, and biological mechanisms of action.
Drug resistance and response research: Investigation of protein-level changes associated with resistance mechanisms to compounds in oncology and antimicrobial research models.
Regenerative and tissue research: Analysis of protein interactions and signaling networks to support research in stem cell biology and tissue engineering models.
Host–pathogen interaction research: Study of host and microbial protein interactions to support research in infection biology and antimicrobial strategy development.
At oloBion, we provide cutting-edge omics services designed to empower researchers in the Biomedicine & Health Research industry. With our state-of-the-art technology and the expertise of our team, we help you unlock the full potential of your analytes (metabolites, lipids and proteins), driving discovery, innovation, and impactful solutions. Our portfolio includes both Untargeted and Targeted metabolomics, lipidomics and proteomics services, as well as ADME-DMPK assays, all tailored to meet the specific needs of your research.
Technique: LC-MS/MS
Untargeted lipidomics analysis for the identification of lipids by LC-MS/MS.The Identification includes a list with superclass, class, lipid name, and InChIKey.
Technique: LC-MS/MS
Untargeted lipidomics analysis for the identification of short chain fatty acids by LC-MS/MS. The indentification includes a list with superclass, class, lipid name, and InChIKey.
Technique: LC-MS/MS
Untargeted lipidomics analysis for the identification of lipids by LC-MS/MS, including oxylipins. The Identification includes a list with superclass, class, lipid name, and InChIKey.
Technique: LC-MS/MS
Untargeted lipidomics analysis for the identification of lipids by LC-MS/MS.The Identification includes a list with superclass, class, lipid name, and InChIKey.
Pharmacolipidomics analysis to identify key lipid classes and determine lipid biomarkers related to bioavailability, metabolism, and compound response, supporting ADME and mechanistic evaluation in preclinical studies.
Targeted lipidomics analysis for the quantification of total fatty acids (FW) (g/100g)
Technique: LC-MS/MS
Target Lipidomics analysis for the identification of specific lipid(s) according to customer requirements
Technique: LC-MS/MS
NextGen proteomics analysis by LC-MS/MS for the identification of proteins in plasma. The identification includes the family and name of the protein.
Technique: LC-MS/MS
NextGen proteomics analysis by LC-MS/MS for the identification of proteins in stool. The identification includes the family and name of the protein.
Technique: LC-MS/MS
NextGen proteomics analysis by LC-MS/MS for the identification of proteins. The identification includes the family and name of the protein.
Pharmacoproteomics analysis to identify key proteins and determine proteomic biomarkers related to drug metabolism, transport, and resistance mechanisms, supporting mechanistic insight in preclinical research.
Technique: LC-MS/MS
Target Proteomics analysis for the identification of specific protein(s) according to customer requirements
In vitro metabolic stability in liver microsomes, hepatocytes, and plasma, with metabolite profiling and reaction phenotyping to support ADME evaluation and compound selection in preclinical drug discovery.
Preclinical pharmacokinetics in rodents and non-rodents, including tissue distribution, renal excretion, and PK/PD studies to characterize exposure and support candidate progression.
Plasma, tissue, and red blood cell binding studies to determine unbound fraction and support exposure assessment, species comparison, and pharmacokinetic modeling in preclinical drug development.
Caco-2 permeability studies to assess compound absorption and P-gp/BCRP transporter interactions, supporting ADME characterization and compound prioritization in preclinical drug discovery.
In vitro CYP inhibition, time-dependent inhibition, induction, and P-gp/BCRP interaction studies to assess drug–drug interaction risk and support ADME evaluation in preclinical development.
Quantitative LC–MS/MS bioanalysis of compounds and biomarkers across plasma, serum, urine, blood, and tissues to support ADME, pharmacokinetics, and preclinical development.
Pharmacoproteomics analysis to identify key proteins and determine proteomic biomarkers related to drug metabolism, transport, and resistance mechanisms, supporting mechanistic insight in preclinical research.
Pharmacolipidomics analysis to identify key lipid classes and determine lipid biomarkers related to bioavailability, metabolism, and compound response, supporting ADME and mechanistic evaluation in preclinical studies.
Pharmacometabolomics studies to identify key metabolic pathways and determine metabolomic biomarkers associated with compound exposure and metabolic response, supporting ADME and mechanistic insight in preclinical research.
Technique: Proximity Extension Assay (PEA) coupled with qPCR, readout NPX **.
Target Proteomics analysis for the identification of 92 specific proteins. Olink® Target 96 Oncology II features putative cancer-related human proteins that participate in biological mechanisms that are central to the initiation and progression of cancer, e.g. angiogenesis, cell-cell signaling, cell-cycle control, and inflammation.
Technique: Proximity Extension Assay (PEA) coupled with qPCR, readout NPX **.
Target Proteomics analysis for the identification of 92 specific proteins. Olink® Target 96 Organ Damage features biomarkers involved in biological response to organ damage with a main focus on stress response, but also on regulation of cell proliferation, the cell cycle, and cell death/apoptosis.
Technique: Proximity Extension Assay (PEA) coupled with qPCR, readout NPX **.
Target Proteomics analysis for the identification of 92 specific proteins. Olink® Target 96 Oncology III includes biomarkers involved in angiogenesis, cell communication, cellular metabolic processes, apoptosis and cell proliferation/differentiation. It is a perfect complement to our Olink® Target 96 Oncology II panel.
Technique: Proximity Extension Assay (PEA) coupled with qPCR, readout NPX **.
Target Proteomics analysis for the identification of 92 specific proteins. Olink® Target 96 Inflammation features the most extensive commercially available biomarker selection for proteins associated with inflammatory diseases such as arthritis, chronic obstructive pulmonary disease, diabetes, psoriasis, and related biological processes. It is compiled to detect a selection of both established and exploratory biomarkers within the inflammation research field.
Technique: Proximity Extension Assay (PEA) coupled with qPCR, readout NPX **.
Target Proteomics analysis for the identification of 92 specific proteins. Olink® Target 96 Metabolism includes biomarkers involved in cellular metabolic processes, cell surface receptor signaling pathways, regulation of phosphorylation and cell adhesion.
Technique: Proximity Extension Assay (PEA) coupled with qPCR, readout NPX **.
Target Proteomics analysis for the identification of 92 specific proteins. The Olink® Target 96 Immuno-Oncology panel covers biomarkers related to immunotherapy/checkpoint molecules and biomarkers involved in promotion and inhibition of tumor immunity, chemotaxis, vascular & tissue remodeling, apoptosis & cell killing, and metabolism & autophagy.
Technique: Proximity Extension Assay (PEA) coupled with qPCR, readout NPX **.
Target Proteomics analysis for the identification of 92 specific proteins. Olink® Target 96 Immune Response includes biomarkers involved in key biological processes such as adaptive immune response, defense response to viruses, lymphocyte activation, inflammatory responses and cytokine-mediated signaling pathways.
Technique: Proximity Extension Assay (PEA) coupled with qPCR, readout NPX **.
Target Proteomics analysis for the identification of 92 specific proteins. Olink® Target 96 Cardiovascular II focuses on cardiovascular and inflammatory biomarkers which have been carefully selected in collaboration with leading experts in the field. It also includes a selection of exploratory proteins with potential as new CVD markers.
Technique: Proximity Extension Assay (PEA) coupled with qPCR, readout NPX **.
Target Proteomics analysis for the identification of 92 specific proteins. Olink® Target 96 Neuro Exploratory consists of a combination of exploratory and established biomarkers with a focus on neurology-related diseases, and biological processes such as axon development, neurogenesis and synapse assembly. This panel is a good complement to Olink® Target 96 Neurology.
Technique: Proximity Extension Assay (PEA) coupled with qPCR, readout NPX **.
Target Proteomics analysis for the identification of 92 specific proteins. The Olink® Target 96 Development panel focuses on biomarkers involved in cell communication and developmental processes.
Technique: Proximity Extension Assay (PEA) coupled with qPCR, readout NPX **.
Target Proteomics analysis for the identification of 92 specific proteins. Olink® Target 96 Cell Regulation includes biomarkers involved in key biological processes such as cell communication, apoptotic processes, the cell cycle and cell differentiation.
Technique: Proximity Extension Assay (PEA) coupled with qPCR, readout NPX **.
Target Proteomics analysis for the identification of 92 specific proteins. The Olink® Target 96 Neurology features well-established biomarkers related to neurobiological processes and neurological diseases (e.g. neural development, axon guidance, synaptic function, or specific conditions such as Alzheimer’s disease). Also includes additional exploratory proteins with broader roles in processes such as cellular regulation, immunology, development and metabolism.
Technique: Proximity Extension Assay (PEA) coupled with qPCR, readout NPX **.
Target Proteomics analysis for the identification of 92 specific proteins. Olink® Target 96 Cardiometabolic features biomarkers involved in cellular metabolic processes, cell adhesion, immune response and complement activation. It is an excellent complement to Olink® Target 96 Cardiovascular II and Olink® Target 96 Cardiovascular III.
Technique: Proximity Extension Assay (PEA) coupled with qPCR, readout NPX **.
Target Proteomics analysis for the identification of 92 specific proteins. As well as the cardiovascular, CVD, and exploratory protein markers included in Cardiovascular II, the Olink® Target 96 Cardiovascular III panel concentrates on cell adhesion biomarkers, carefully selected in collaboration with leading cardiovascular scientists.
Technique: Proximity Extension Assay (PEA) coupled with qPCR, readout pg/mL.
Target Proteomics analysis for the identification of 44 specific proteins. Olink® Target 48 Immune Surveillance panel is a high-performance solution for immune response and inflammation-related studies. The carefully selected range of biomarkers in this panel provides a great mean for studying key pathways related to cytokine signalling, inflammatory processes, and immune response in cancer.
Technique: Proximity Extension Assay (PEA) coupled with qPCR, readout pg/mL.
Target Proteomics analysis for the identification of 45 specific proteins. Olink® Target 48 Cytokine panel is the high-performance solution for cytokine studies and inflammation-related diseases, with absolute or relative quantification. The thorough selection of biomarkers ensures that the most important proteins covering key pathways related to cytokine signaling and inflammatory processes are well covered.
Technique: Proximity Extension Assay (PEA) coupled with qPCR, readout pg/mL.
Target Proteomics analysis for the identification of 5 to 30 specific protein(s) selected from a library of 197 proteins, according to customer requirements.
Technique: Proximity Extension Assay (PEA) coupled with qPCR, readout pg/mL.
Target Proteomics analysis for the identification of 21 specific proteins. A panel targeting biomarkers involved in biological pathways central for immuno-oncology research e.g., angiogenesis, growth regulation, apoptosis and immunity.
Technique: Proximity Extension Assay (PEA) coupled with qPCR, readout pg/mL.
Target Proteomics analysis for the identification of 21 specific proteins. Assays carefully selected for their scientifically proven importance in the uncontrolled inflammatory response condition commonly referred to as cytokine storm.
Technique: Proximity Extension Assay (PEA) coupled with qPCR, readout pg/mL.
Target Proteomics analysis for the identification of 26 specific proteins. Includes 26 biomarkers crucial for studying inflammation and providing deeper insights into the immune landscape.
Technique: Proximity Extension Assay (PEA) coupled with qPCR, readout pg/mL.
Target Proteomics analysis for the identification of 21 specific proteins. Curated based on UK Biobank proteomics data to include top biomarkers associated with type 2 diabetes.
Technique: Proximity Extension Assay (PEA) coupled with qPCR, readout pg/mL.
Target Proteomics analysis for the identification of 21 specific proteins. Aging is a multifaceted process characterized by systemic chronic inflammation. This carefully curated panel includes biomarkers crucial in age-related changes of the immune system.
Technique: Proximity Extension Assay (PEA) coupled with qPCR, readout pg/mL.
Target Proteomics analysis for the identification of 20 specific proteins. Interferon (IFN) inflammation is associated with immunotherapy resistance in melanoma. This panel is developed together with Dr. Mehta and is based on findings from the Nature Immunology paper “In vivo CRISPR screens reveal the landscape of immune evasion pathways across cancer” (Manguso et al.)
Technique: Proximity Extension Assay (PEA) coupled with qPCR, readout pg/mL.
Target Proteomics analysis for the identification of 5 specific proteins. Combines 5 key proinflammatory markers for targeted studies of inflammation and immune response.
Technique: Proximity Extension Assay (PEA) coupled with qPCR, readout pg/mL.
Target Proteomics analysis for the identification of 21 specific proteins. This panel includes the most important cytokines characterizing the Th1/Th2/Th17 inflammatory profiles, thereby providing the ultimate solution for studies of the immune system.
Transform your omics data into actionable insights with oloMAP Portal, our interactive platform for advanced statistical analysis and visualization.
Combine multiple omics datasets to uncover relationships between biological layers, gain a holistic view of underlying processes and identify potential biomarkers.
Comprehensive biological interpretation from our experts to connect omics data with biological pathways, highlighting relevant mechanisms and potential biomarkers tailored to your study.
01
Contact and
Proposal
02
Send Samples
to the Lab
03
Sample Reception
and Processing
04
Mass Spectrometry
Analysis
05
Gain Insight into
oloMAP Portal
Standard Delivery Time:
6 weeks
Fast-track option available
Minimum Sample Amount:
Consult our experts for guidance
on sample requirements
Discount:
Associated with the number of
samples and multi-omics analysis
Partner with us to explore the power of our analysis in your field. Our team is ready to guide you through the process and deliver insights tailored to your research or industry needs.
Contact us today to discuss your project or schedule a consultation. Together, we’ll advance innovation through omics!